Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis
Authors' conclusion
Tirzepatide outperformed basal insulins in controlling blood glucose, body weight, blood pressure, and lipids in subjects with T2D and is generally well-tolerated except for its higher gastrointestinal AEs.
Study context
- Population
- Subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs
- Participants
- 4,339 subjects3 RCTs
- Comparison
- Once-weekly tirzepatide vs once-daily basal insulins as add-on therapy
- Outcome
- Change from baseline in HbA1c
Pooled result
As reported in the abstract
Each group vs basal insulinsMD, % (95% CI)P value
Tirzepatide 5 mg
−0.89(−1.23 to −0.54)
P < 0.00001 for allTirzepatide 10 mg
−1.11(−1.42 to −0.79)
P < 0.00001 for allTirzepatide 15 mg
−1.23(−1.48 to −0.97)
P < 0.00001 for allFurther pooled results
Proportion achieving hemoglobin A1c (HbA1c) <7.0%, <6.5% and <5.7%
- Significantly greater with tirzepatide than basal insulin
Body weight and blood pressure
- Greater reductions with tirzepatide than basal insulins
Lipid profile
- More favorable impact with tirzepatide
Safety
Hypoglycemia
- Less frequent with tirzepatide
Gastrointestinal adverse events (AEs) and serious AEs
- Gastrointestinal AEs more frequent with tirzepatide (all doses) than basal insulin
- Serious AEs comparable between the 2 groups
Original publication
Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis. Endocr Pract. Published 11 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →